The U.S. Food and Drug Administration (FDA) granted full approval to Pfizer-BioNTech’s coronavirus vaccine for those aged 16 and older on Monday.
The two-dose immunization was the first to receive emergency use authorization from federal regulators in December 2020 and will now be first to be licensed.
Full approval by the FDA could push more Americans to get the COVID-19 vaccine because it might reduce their fears about the safety of the shot.
It may also lead to more vaccine mandates with businesses feeling more comfortable requiring workers to get a jab that has full authorization.
Pfizer said on Monday the vaccine will continue to be available for 12-to-15-year-olds and as third doses for immunocompromised people under emergency use only.
President Joe Biden shared the news on Twitter and encouraged Americans to keep rolling up their sleeves.
The FDA has officially approved the Pfizer COVID-19 vaccine. While all three COVID vaccines have met FDA’s strict standards for emergency use, this FDA approval should give added confidence that this vaccine is safe and effective,’ he wrote.
‘If you’re not vaccinated yet, now is the time.’
The FDA gave the Pfizer-BioNTech COVID-19 vaccine full approval by Monday. Pictured: A nurse hold a vial of the Pfizer-BioNTech vaccine at a clinic in Atlanta, Georgia, August 17
The full approval may help convince vaccine hesitant Americans to get the shot. Pictured: A student at California State University Long Beach receives a first dose of the Pfizer COVID-19 vaccine on campus, August 11
‘The FDA’s approval of this vaccine is a milestone as we continue to battle the COVID-19 pandemic,’ acting FDA commissioner Dr Janet Woodcock said in a statement.
‘While this and other vaccines have met the FDA’s rigorous, scientific standards for emergency use authorization, as the first FDA-approved COVID-19 vaccine, the public can be very confident that this vaccine meets the high standards for safety, effectiveness, and manufacturing quality the FDA requires of an approved product.
‘Today’s milestone puts us one step closer to altering the course of this pandemic in the U.S.’
Prior to Monday, Pfizer’s vaccine was only approved for use on an emergency basis, meaning it was considered somewhat experimental despite data showing it is safe and effective.
Emergency use authorization requires less clinical trial data, with the FDA only requiring two months of follow-up before approving the shot for those 16 and older last year compared to six months for full approval.
President Joe Biden celebrated the news and encouraged Americans to keep getting vaccinated
The data came from Pfizer’s trial last year of 44,000 people, of whom half received the shots.
‘Based on the longer-term follow-up data that we submitted, today’s approval for those aged 16 and over affirms the efficacy and safety profile of our vaccine at a time when it is urgently needed,’ said Pfizer CEO Albert Bourla in a statement.
‘I am hopeful this approval will help increase confidence in our vaccine.’
The emergency use designation is also intended to be temporary.
With full approval, companies and schools may feel more comfortable requiring employees and students to get it.
‘If vaccines are fully authorized, that would take that excuse [for not getting vaccinated] off the table,’ Dr William Schaffner, a professor of preventive medicine and infectious diseases at the Vanderbilt University Medical Center, told DailyMail.com in an interview last month.
‘If fully licensed, I think that movement of [vaccine] mandates would accelerate and generate lots of vaccinations.’
After lagging vaccination rates over the summer, the pace has increased again with a seven-day rolling average of more than 889,00, according to data from the Centers for Disease Control and Prevention (CDC).
That figure is 23 percent higher than the 718,000 average recorded one week earlier and the highest number seen since July 5.
Experts believe the full approval will help boost vaccination numbers even further but will not change the minds of most vaccine hesitant people.
Dr Jesse Goodman, a former chief scientist at the FDA and current professor of medicine and infectious diseases at Georgetown University, told The Washington Post: ‘It will provide an additional nudge but not make a huge difference
The decision will also allow the vaccine makers to market their shots directly to the general public.
According to the FDA, the vaccine will be marketed under the name Comirnaty.
Critics had been pushing the FDA to move more quickly to approve the vaccine, after Pfizer filed the application on May 7, as COVID-19 cases rose in the U.S.
Average infections have increased 182 percent over the last month from 52,000 per day to 147,000 per day.
Experts said the fact that 204 million doses had been administered since December 2020 with few reports of side effects showed the vaccine is safe and effective.
‘It’s been remarkably fast,’ Holly Fernandez Lynch, a bioethics expert and attorney at the University of Pennsylvania, told The post.
‘You can’t have it both ways. You can’t have people saying they won’t get vaccinated until there’s full approval and then say the FDA has to hurry up.’
